Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes
Publication

Publications

The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes

Title
The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes
Type
Another Publication in an International Scientific Journal
Year
2018
Authors
Chilton, RJ
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Gallegos, KM
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Silva Cardoso, J
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Oliveros, R
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Pham, S
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 18
ISSN: 1534-4827
Publisher: Springer Nature
Indexing
Other information
Authenticus ID: P-00P-VG1
Abstract (EN): Purpose of Review: To evaluate the treatment of type 2 diabetes from a cardiologist¿s view. Recent Findings: A new era in the treatment of type 2 diabetes began for the cardiologist in 2015 with the publication of the EMPA-REG outcome trial finding a significant reduction in CV death with empagliflozin (oral sodium-glucose co-transporter-2 [SGLT2] inhibitor) in patients with type 2 diabetes at increased cardiovascular risk. Shortly thereafter, the injectable glucagon-like peptide agonists (GLP-1) liraglutide and semaglutide found a significant reduction in composite major cardiovascular events (CV death, non-fatal MI, or stroke). Both classes have demonstrated significant renal protection when added to usual care. Moreover, there may be some exciting new benefits of SGLT2 inhibitors for patients with heart failure. These research studies are underway. Summary: These two new classes of cardiovascular drugs for type 2 diabetes usher in a new era for the cardiologist who sees greater than 50% of patients with diabetes. The off-target effect of these agents is different as with all new cardiovascular compounds. While safety profiles in these populations are consistent with the known effects of these classes, new off-target effects have been seen with some agents in this class. Ongoing collaboration between cardiologists and other care providers remains important in the implementation of the evidence and care of patients with type 2 diabetes. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
Language: English
Type (Professor's evaluation): Scientific
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Impact of Gestational Diabetes Mellitus in the Maternal-to-Fetal Transport of Nutrients (2015)
Article in International Scientific Journal
Araújo JR; Elisa Keating; Martel, F
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-15 at 00:49:58 | Privacy Policy | Personal Data Protection Policy | Whistleblowing